Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictability of response of aflibercept treatment for wet age-related macular degeneration under the treat-and-moderate extend regimen (TMER)
2015-001394-41Phase 4Completed
- Sponsor
- Raimo Tuuminen
- Start
- Apr 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Raimo Tuuminen. Primary endpoints: Mean change from baseline best corrected visual acuity at 24 months and Number of aflibercept injections over 24 months. Started Apr 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2015-001394-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001394-41.